INS and cystic fibrosis: Regarding Ivacaftor therapy, a five-year prospective registry study first showed a reduction in the CFRD incidence [19], whereas a significant improvement in insulin secretion, in particular its first phase measured during a mixed-meal tolerance test, was observed in young CF patients without diabetes [20].